Background
Axsome Therapeutics developed AXS-07, an investigational migraine treatment. From December 2019 through April 2022, Axsome issued public statements estimating an FDA New Drug Application filing in the fourth quarter of 2020, followed by multiple revised timelines. The company allegedly omitted chemistry, manufacturing, and control (CMC) deficiencies that made the estimated filing dates “unlikely” and overstated the drug’s regulatory prospects.
On April 25, 2022, Axsome disclosed that the FDA had identified unresolved CMC issues during its NDA review. The company expected a Complete Response Letter denying approval. Axsome’s stock price fell $8.60 per share. Parallel securities and derivative litigation began in federal court in May 2022. The federal securities action settled in February 2026.
Delaware stockholders John Wickstrom and John Gildea sent books and records demands in April and May 2025, respectively. Wickstrom’s demand was initially emailed to investor relations but counsel did not follow up for three weeks, eventually requesting Axsome’s outside counsel forward it to the company. Gildea’s demand was properly served. Axsome produced documents in September 2025. Wickstrom filed a derivative complaint on September 23, 2025, and Gildea filed six days later. The plaintiffs alleged breach of fiduciary duty, unjust enrichment, and waste of corporate assets based on the allegedly false statements about AXS-07’s regulatory prospects.
The Court’s Holding
Vice Chancellor Will held that the derivative claims were time-barred under the doctrine of laches. The plaintiffs’ claims accrued when Axsome disseminated the challenged statements, with the latest accrual date being April 22, 2022, when the FDA disclosed the CMC issues. Under Delaware law, a three-year statute of limitations applies by analogy to breach of fiduciary duty, unjust enrichment, and waste claims. To sue timely, the plaintiffs were required to file by April 22, 2025. Wickstrom’s filing on September 23, 2025, was more than five months late.
The court rejected the plaintiffs’ argument that their books and records demands tolled the statute of limitations. While earlier Delaware cases had permitted tolling during pending Section 220 enforcement actions where a plaintiff was “aggressively asserting its claims,” the court clarified that service of a demand alone does not automatically toll the limitations period. Rather, only the diligent filing of a Section 220 enforcement action—a summary proceeding with expedited discovery—can support tolling. Wickstrom’s attempt to email the demand to investor relations before the deadline constituted improper service and was pursued without deliberate speed; moreover, he later stipulated that his demand was not validly served until May 14, 2025—well after the statute expired. Gildea’s demand was served after the limitations period had already run.
The defendants invoked a presumption of prejudice by virtue of the late filing. The plaintiffs failed to rebut this presumption by demonstrating “unusual circumstances or extraordinary conditions.” The existence of parallel federal derivative litigation did not prevent the plaintiffs from suing in Delaware and therefore did not constitute an extraordinary circumstance. The court dismissed the complaint with prejudice.
Key Takeaways
- Delaware strictly enforces the three-year statute of limitations for derivative claims through the laches doctrine; filing after expiration triggers a presumption of prejudice to defendants.
- Service of a books and records demand alone does not toll the statute of limitations; only the diligent filing of a Section 220 enforcement action can support tolling.
- Stockholders who investigate alleged misconduct must act with “deliberate speed”; an out-of-court demand pursued without prompt follow-up and without filing a Section 220 enforcement action does not evidence the aggressive assertion of rights required for tolling.
- Parallel litigation in another jurisdiction, standing alone, does not prevent timely filing in Delaware and does not constitute an extraordinary circumstance rebutting the prejudice presumption.
Why It Matters
This decision provides critical guidance on the interaction between Section 220 books and records demands and Delaware’s statute of limitations for derivative claims. The court clarified that Delaware will not reward dilatory tactics; stockholders cannot delay filing a derivative suit and then attempt to bootstrap tolling by belatedly sending a demand letter. The distinction between merely transmitting a demand and diligently pursuing a Section 220 enforcement action has real consequences for the running of the limitations period.
For defendants, the ruling offers finality protection: even if parallel litigation proceeds in federal court or another jurisdiction, the Delaware statute of limitations provides an independent bar to late-filed derivative claims. For stockholders, the message is clear: investigate quickly or risk losing rights altogether. The decision also reflects Delaware’s intent to encourage prompt, focused Section 220 actions as the vehicle through which stockholders develop factual bases for derivative litigation, rather than permitting open-ended pre-suit investigation through informal demand letters.